The latest news about Montara
Endpoints Exclusive: Startup aims to tackle “undruggable” neuro targets with tech from Kevan Shokat’s UCSF lab
July 30, 2024 | San Francisco, CA
This Endpoints News article explores the creation of Montara Therapeutics by Kevan Shokat and Nicholas Hertz after selling their first neuro startup to AbbVie.
Montara Therapeutics Closes $8 Million Seed Round Led by SV Health Investors’ Dementia Discovery Fund and Two Bear Capital to Develop Safer, More Effective Neuroscience Drugs Using a Novel Brain-Only Pharmacology Approach
July 30, 2024 | San Francisco, CA
Montara Therapeutics, Inc. (‘Montara’), a therapeutics company aiming to revolutionize the discovery and development of brain-targeting drugs, announced today the closing of an oversubscribed $8 million seed financing led by SV Health Investors’ Dementia Discovery Fund and co-lead Two Bear Capital. Dolby Family Ventures and KdT Ventures also participated in the round.
